PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18660817.
- Also identified by DOI 10.1038/nm.1852.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sclerosis and reduced microvessel density characterize advanced stages of muscular dystrophy and hamper cell or gene delivery, precluding treatment of most individuals with Duchenne muscular dystrophy. Modified tendon fibroblasts expressing an angiogenic factor (placenta growth factor, PlGF) and a metalloproteinase (matrix metalloproteinase-9, MMP-9) are able to restore a vascular network and reduce collagen deposition, allowing efficient cell therapy in aged dystrophic mice. These data open the possibility of extending new therapies to currently untreatable individuals.
Medical subject headings
- Cell- and Tissue-Based Therapy
- Matrix Metalloproteinase 9
- Muscle, Skeletal
- Muscular Dystrophy, Duchenne
- Pregnancy Proteins